

BYSTOLIC

Products Affected

Step 2:

- BYSTOLIC 10 MG TABLET
- BYSTOLIC 2.5 MG TABLET
- BYSTOLIC 20 MG TABLET
- BYSTOLIC 5 MG TABLET

Details

Criteria	If the patient has tried a Step 1 drug within the past 120 days, then authorization for a Step 2 drug may be given. Step 1 Drug(s): generic beta-blockers, Sorine. Step 2 Drug(s): Bystolic.
-----------------	--

DIFICID

Products Affected

Step 2:

- DIFICID 200 MG TABLET

Details

Criteria	If the patient has tried a Step 1 drug within the past 120 days, then authorization for a Step 2 drug may be given. Step 1 Drug(s): metronidazole, vancomycin. Step 2 Drug(s): Dificid
-----------------	--

DPP-4

Products Affected

Step 2:

- ALOGLIPTIN 12.5 MG TABLET
- ALOGLIPTIN 12.5 MG-METFORMIN 1,000 MG TABLET
- ALOGLIPTIN 12.5 MG-METFORMIN 500 MG TABLET
- ALOGLIPTIN 25 MG TABLET
- ALOGLIPTIN 6.25 MG TABLET
- KAZANO 12.5 MG-1,000 MG TABLET
- KAZANO 12.5 MG-500 MG TABLET
- KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE
- KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE
- KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE
- NESINA 12.5 MG TABLET
- NESINA 25 MG TABLET
- NESINA 6.25 MG TABLET
- ONGLYZA 2.5 MG TABLET
- ONGLYZA 5 MG TABLET

Details

Criteria	
	If the patient has tried a Step 1 drug within the past 120 days, then authorization for a Step 2 drug may be given. Step 1 Drug(s): Januvia, Janumet, Janumet XR, Tradjenta, Jentadueto, Jentadueto XR. Step 2 Drug(s): Onglyza, Kombiglyze, Nesina, Kazano, Alogliptin, and Alogliptin/metformin.

NASAL STEROIDS

Products Affected

Step 2:

- BECONASE AQ 42 MCG (0.042 %) NASAL SPRAY
- DYMISTA 137 MCG-50 MCG/SPRAY NASAL SPRAY
- OMNARIS 50 MCG NASAL SPRAY
- QNASL 80 MCG/ACTUATION NASAL AEROSOL SPRAY
- ZETONNA 37 MCG/ACTUATION NASAL HFA INHALER

Details

Criteria	If the patient has tried a Step 1 drug within the past 120 days, then authorization for a Step 2 drug may be given. Step 1 Drug(s): generic nasal steroid. Step 2 Drug(s): Beconase AQ, Dymista, Omnaris, Qnasl, Zetonna. Beconase AQ will be approved first line for a diagnosis of nasal polyps.
-----------------	--

OPHTHALMIC PROSTAGLANDINS

Products Affected

Step 2:

- BIMATOPROST 0.03 % EYE DROPS
- LUMIGAN 0.01 % EYE DROPS
- TRAVATAN Z 0.004 % EYE DROPS
- ZIOPTAN (PF) 0.0015 % EYE DROPS
IN A DROPPERETTE

Details

Criteria	If the patient has tried a Step 1 drug within the past 120 days, then authorization for a Step 2 drug may be given. Step 1 Drug(s): latanoprost. Step 2 Drug(s): Lumigan, Travatan Z, Zioptan, Bimatoprost.
-----------------	---

ULORIC

Products Affected

Step 2:

- ULORIC 40 MG TABLET
- ULORIC 80 MG TABLET

Details

Criteria	If the patient has tried a Step 1 drug within the past 120 days, then authorization for a Step 2 drug may be given. Step 1 Drug(s): allopurinol. Step 2 Drug(s): Uloric.
-----------------	--

Index

A

ALOGLIPTIN 12.5 MG TABLET	3
ALOGLIPTIN 12.5 MG-METFORMIN 1,000 MG TABLET	3
ALOGLIPTIN 12.5 MG-METFORMIN 500 MG TABLET	3
ALOGLIPTIN 25 MG TABLET	3
ALOGLIPTIN 6.25 MG TABLET	3

B

BECONASE AQ 42 MCG (0.042 %) NASAL SPRAY	4
BIMATOPROST 0.03 % EYE DROPS	5
BYSTOLIC 10 MG TABLET	1
BYSTOLIC 2.5 MG TABLET	1
BYSTOLIC 20 MG TABLET	1
BYSTOLIC 5 MG TABLET	1

D

DIFICID 200 MG TABLET	2
DYMISTA 137 MCG-50 MCG/SPRAY NASAL SPRAY	4

K

KAZANO 12.5 MG-1,000 MG TABLET ..	3
KAZANO 12.5 MG-500 MG TABLET	3
KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE	3
KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE	3

KOMBIGLYZE XR 5 MG-500 MG

TABLET,EXTENDED RELEASE	3
-------------------------------	---

L

LUMIGAN 0.01 % EYE DROPS.....	5
-------------------------------	---

N

NESINA 12.5 MG TABLET	3
NESINA 25 MG TABLET	3
NESINA 6.25 MG TABLET	3

O

OMNARIS 50 MCG NASAL SPRAY.....	4
ONGLYZA 2.5 MG TABLET	3
ONGLYZA 5 MG TABLET	3

Q

QNASL 80 MCG/ACTUATION NASAL AEROSOL SPRAY	4
---	---

T

TRAVATAN Z 0.004 % EYE DROPS	5
------------------------------------	---

U

ULORIC 40 MG TABLET	6
ULORIC 80 MG TABLET	6

Z

ZETONNA 37 MCG/ACTUATION NASAL HFA INHALER.....	4
ZIOPTAN (PF) 0.0015 % EYE DROPS IN A DROPPERETTE.....	5